# OnCo record tak-928 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tak-928/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tak-928" ;
  schema:name "TAK-928"@en ;
  schema:description "TAK-928 is an experimental bispecific antibody from Takeda in phase 3 trials for non-small-cell lung cancer, aimed at PD-1 and CD25 (IL-2 receptor alpha)."@en ;
  schema:url <https://onco.cc/drugs/tak-928/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=TAK-928> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "bispecific antibody" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/cd25/> ;
  onco:companies <https://onco.cc/companies/takeda/> ;
  onco:trials <https://onco.cc/trials/nct07217301/> .